Ann: Non-Renounceable Pro-Rata Rights Issue - Rev, page-55

re: Ann: Non-Renounceable Pro-Rata Rights Iss... OscarA

So presumably the answer is that sales for Sept 2008 did increase, but payment had not then been received. So we are both right.

Mind you, Bioeffective A320 retails for $29.95. Let's assume that SLA gets two thirds of that (maybe they get more, maybe they get less - I am not in this sort of business).

What does this estimate do for the four fold increase in Bioeffective sales in the September quarter? Sales of 6,115 x $20 per unit suggest a total $122,300 for the September quarter.

Let's get this into perspective. According to the annual report, the directors of SLA took a total of $421,688 in salaries and consulting fees for the year ended June 2008. That works out at $105,422 a quarter.

So even cash from this four fold increase in sales of Bioeffective A320 only just keeps the directors safe with their emoluments. There is $16,878 left over as working capital.

Therefore Bioeffective A320 is a scraggy cash cow, trying to suckle deservedly thirsty directors.